Development of an artificial intelligence based radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in breast cancer: a multicenter study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063406

Enrollment

Unknown

Registered

2022-09-06

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:Pathological results of radical surgical resection

Index test:An artificial intelligence based radiopathomics model

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients diagnosed with locally advanced breast cancer from September 1, 2022 to November 30, 2022 in our hospital and intending to undergo neoadjuvant chemotherapy were included: 1. Patients were examined by MRI prior to treatment and had available digital pathology slide scan image information; 2. Complete surgical pathology results after treatment; 3.Clear image quality.

Exclusion criteria

Exclusion criteria: 1. There is a history of prior chemoradiotherapy or malignancy; 2. Incomplete clinical information.

Design outcomes

Secondary

Measure	Time frame
sensitivity;specificity;accuracy;	—

Primary

Measure	Time frame
Area under receiver operating characteristic curve;	—

Countries

China

Contacts

Public ContactMao Ning

Yantai Yuhuangding Hospital

maoning@pku.edu.cn+86 13105351972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026